N E Carlozzi1, N R Downing2, M K McCormack3, S G Schilling4, J S Perlmutter5,6, E A Hahn7, J S Lai8,9, S Frank10, K A Quaid11, J S Paulsen12,13,14, D Cella7,8,9, S M Goodnight15, J A Miner15, M A Nance16. 1. Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA. carlozzi@med.umich.edu. 2. College of Nursing, The University of Iowa, Iowa City, IA, USA. 3. Department of Pathology, Rowan University, Piscataway, NJ, USA. 4. Institute for Social Research, University of Michigan, Ann Arbor, MI, USA. 5. Departments of Neurology, Radiology, and Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, MO, USA. 6. Program in Occupational Therapy and Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO, USA. 7. Department of Medical Social Sciences, Northwestern University, Chicago, IL, USA. 8. Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Northwestern University, Evanston, IL, USA. 9. Institute for Health Services Research and Policy Studies, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 10. Beth Israel Deaconess Medical Center, Boston, MA, USA. 11. Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA. 12. Department of Psychiatry, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA. 13. Department of Neurology, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA. 14. Department of Psychology, The University of Iowa, Iowa City, IA, USA. 15. Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA. 16. Hennepin County Medical Center, Minneapolis, MN, USA.
Abstract
PURPOSE: Huntington disease (HD) is an incurable terminal disease. Thus, end of life (EOL) concerns are common in these individuals. A quantitative measure of EOL concerns in HD would enable a better understanding of how these concerns impact health-related quality of life. Therefore, we developed new measures of EOL for use in HD. METHODS: An EOL item pool of 45 items was field tested in 507 individuals with prodromal or manifest HD. Exploratory and confirmatory factor analyses (EFA and CFA, respectively) were conducted to establish unidimensional item pools. Item response theory (IRT) and differential item functioning analyses were applied to the identified unidimensional item pools to select the final items. RESULTS: EFA and CFA supported two separate unidimensional sets of items: Concern with Death and Dying (16 items), and Meaning and Purpose (14 items). IRT and DIF supported the retention of 12 Concern with Death and Dying items and 4 Meaning and Purpose items. IRT data supported the development of both a computer adaptive test (CAT) and a 6-item, static short form for Concern with Death and Dying. CONCLUSION: The HDQLIFE Concern with Death and Dying CAT and corresponding 6-item short form, and the 4-item calibrated HDQLIFE Meaning and Purpose scale demonstrate excellent psychometric properties. These new measures have the potential to provide clinically meaningful information about end-of-life preferences and concerns to clinicians and researchers working with individuals with HD. In addition, these measures may also be relevant and useful for other terminal conditions.
PURPOSE:Huntington disease (HD) is an incurable terminal disease. Thus, end of life (EOL) concerns are common in these individuals. A quantitative measure of EOL concerns in HD would enable a better understanding of how these concerns impact health-related quality of life. Therefore, we developed new measures of EOL for use in HD. METHODS: An EOL item pool of 45 items was field tested in 507 individuals with prodromal or manifest HD. Exploratory and confirmatory factor analyses (EFA and CFA, respectively) were conducted to establish unidimensional item pools. Item response theory (IRT) and differential item functioning analyses were applied to the identified unidimensional item pools to select the final items. RESULTS:EFA and CFA supported two separate unidimensional sets of items: Concern with Death and Dying (16 items), and Meaning and Purpose (14 items). IRT and DIF supported the retention of 12 Concern with Death and Dying items and 4 Meaning and Purpose items. IRT data supported the development of both a computer adaptive test (CAT) and a 6-item, static short form for Concern with Death and Dying. CONCLUSION: The HDQLIFE Concern with Death and Dying CAT and corresponding 6-item short form, and the 4-item calibrated HDQLIFE Meaning and Purpose scale demonstrate excellent psychometric properties. These new measures have the potential to provide clinically meaningful information about end-of-life preferences and concerns to clinicians and researchers working with individuals with HD. In addition, these measures may also be relevant and useful for other terminal conditions.
Entities:
Keywords:
End of life; HDQLIFE; Health-related quality of life; Huntington disease; Neuro-QoL; PROMIS; Patient-reported outcome (PRO)
Authors: Janet K Williams; Cheryl Erwin; Andrew R Juhl; Michelle Mengeling; Yvonne Bombard; Michael R Hayden; Kimberly Quaid; Ira Shoulson; Sandra Taylor; Jane S Paulsen Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-09 Impact factor: 3.568
Authors: Daren K Heyland; Deborah J Cook; Graeme M Rocker; Peter M Dodek; Demetrios J Kutsogiannis; Yoanna Skrobik; Xuran Jiang; Andrew G Day; S Robin Cohen Journal: Palliat Med Date: 2010-07-06 Impact factor: 4.762
Authors: Rebecca E Ready; Nicholas R Boileau; Stacey K Barton; Jin-Shei Lai; Michael K McCormack; David Cella; Nora E Fritz; Jane S Paulsen; Noelle E Carlozzi Journal: J Huntingtons Dis Date: 2019
Authors: Noelle E Carlozzi; E A Hahn; S A Frank; J S Perlmutter; N D Downing; M K McCormack; S Barton; M A Nance; S G Schilling Journal: J Neurol Date: 2017-11-15 Impact factor: 4.849
Authors: Melissa Wesson; Nicholas R Boileau; Joel S Perlmutter; Jane S Paulsen; Stacey K Barton; Michael K McCormack; Noelle E Carlozzi Journal: J Huntingtons Dis Date: 2018
Authors: Nancy R Downing; Siera Goodnight; Sena Chae; Joel S Perlmutter; Michael McCormack; Elizabeth Hahn; Stacey K Barton; Noelle Carlozzi Journal: Am J Hosp Palliat Care Date: 2017-06-28 Impact factor: 2.500
Authors: Elizabeth A Hahn; Nancy R Downing; Julie C Stout; Jane S Paulsen; Becky Ready; Siera Goodnight; Jin-Shei Lai; Jennifer A Miner; Noelle E Carlozzi Journal: Qual Life Res Date: 2017-12-06 Impact factor: 4.147
Authors: Nora E Fritz; Nicholas R Boileau; Julie C Stout; Rebecca Ready; Joel S Perlmutter; Jane S Paulsen; Kimberly Quaid; Stacey Barton; Michael K McCormack; Susan L Perlman; Noelle E Carlozzi Journal: J Neuropsychiatry Clin Neurosci Date: 2018-03-21 Impact factor: 2.198
Authors: N E Carlozzi; S G Schilling; J-S Lai; J S Paulsen; E A Hahn; J S Perlmutter; C A Ross; N R Downing; A L Kratz; M K McCormack; M A Nance; K A Quaid; J C Stout; R C Gershon; R E Ready; J A Miner; S K Barton; S L Perlman; S M Rao; S Frank; I Shoulson; H Marin; M D Geschwind; P Dayalu; S M Goodnight; D Cella Journal: Qual Life Res Date: 2016-08-13 Impact factor: 4.147
Authors: N E Carlozzi; N R Downing; S G Schilling; J-S Lai; S M Goodnight; J A Miner; S A Frank Journal: Qual Life Res Date: 2016-05-03 Impact factor: 4.147